.jpg?format=webp&width=780)
This study aimed to investigate the effectiveness, safety, and tolerability of ziritaxestat, a selective autotaxin inhibitor, in patients with early diffuse cutaneous systemic sclerosis (dcSSc). The 24-week study involved adults with dcSSc who were given either ziritaxestat or a placebo. The primary measure of efficacy was the change in modified Rodnan skin score (MRSS) after 24 weeks. The results showed that patients receiving ziritaxestat had a significantly greater reduction in MRSS compared to those on placebo. Ziritaxestat was well-tolerated, with headache and diarrhea being the most common side effects. Biomarker analysis indicated that ziritaxestat may reduce fibrosis. Overall, ziritaxestat shows potential for improving skin involvement in patients with dcSSc.
Like
Save
Share